ABUS vs WFC · P/E 5.4, rev $6.2M vs P/E 15, $272.05B cap
Arbutus Biopharma Corp (ABUS) versus Wells Fargo & Company (WFC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Wells Fargo & Company (WFC) is a banks - diversified company listed on US. It is led by Charlie Scharf.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
WFC does not have a complete income-statement cache yet.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. WFC currently screens at market cap $272.05B and trailing P/E 15.0.
Not investment advice. Open the ABUS and WFC stock pages for the full models.
Not investment advice.